|Bid||172.05 x 1200|
|Ask||172.14 x 1100|
|Day's range||159.41 - 173.66|
|52-week range||115.61 - 497.49|
|Beta (5Y monthly)||1.65|
|PE ratio (TTM)||4.76|
|Earnings date||03 Aug 2022 - 08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||219.33|
Yahoo Finance health reporter Anjalee Khemlani outlines the events surrounding the FDA's ban on Juul products and e-cigarettes, as well as Pfizer's Paxlovid COVID-19 treatment pill receiving an Emergency Use Authorization from the FDA.
What happened Shares of Moderna (NASDAQ: MRNA) were trading 6.9% higher as of 11:07 a.m. ET on Thursday, though the company hadn't announced any new developments. Instead, those gains appear to be primarily the result of a broader stock market bounce.
This should be especially good news for Moderna (NASDAQ: MRNA). The first hurdle is that Moderna must obtain FDA Emergency Use Authorization (EUA) for its omicron booster. The second hurdle for Moderna is to secure an additional supply deal with the U.S. government that includes omicron boosters.